Myriad Genetics, Inc.

US$5.92As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:MYGNHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (11.31%)
Div yield —
ROE (40.23%)
Diagnostics & Research
Beta (5Y) 1.61
PE TTM —
TSR TTM (26.37%)
Mkt cap US$567.9M
ROIC (27.80%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$6.53
10.36%
(35.49%)
Hold 12|10|7|6|8
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.08
0.08
0.09
0.10
17.90%
9.10%
7.37%
23.36%
Revenue$M
47.91
47.21
49.79
48.44
2.23%
1.01%
7.02%
3.31%
Peers (US$567.9M)
Cap (US$)
PE
1.094B
—
Capital
TTM
5Y
10Y
Leveragex
1.252
0.582
0.546
EBIT/Intx
0.787
0.195
0.201
Own earn%
(34.77)
(64.51)
(89.71)
Sh yield%
24.01
54.66
50.05
Owners
Insiders/Inst%
0.80
22.57
Short interest%
4.61
SBC / revenue%
0.84
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
15
Op margin range%
21–26
$1 testx
—
Incr. ROIC%
10